Cytochrome P450 1B1 expression in glial cell tumors: An immunotherapeutic target

Clinical Cancer Research

Volumn 13, Issue 12, 2007, Pages 3559-3567

  Barnett, Julia A ^c   Urbauer, Diana L ^a   Murray, Graeme I ^b   Fuller, Gregory N ^a   Heimberger, Amy B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 1B1;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTROCYTE; CANCER GRADING; CANCER IMMUNOTHERAPY; CELL VIABILITY; CHILD; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; GENE TARGETING; GLIA CELL; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MEDICAL RESEARCH; MULTIVARIATE ANALYSIS; OLIGODENDROGLIOMA; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL TIME; TISSUE MICROARRAY; UNIVARIATE ANALYSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENE EXPRESSION; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PROGNOSIS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 34250754487     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2430     Document Type: Article

References (31)

1. Maecker B, Sherr DH, Vonderheide RH, et al. The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells. Blood 2003;102:3287-94.
2. Murray GI, Taylor MC, McFadyen MC, et al. Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res 1997;57:3026-31.
3. Muskhelishvili L, Thompson PA, Kusewitt DF, Wang C, Kadlubar FF. In situ hybridization and immunohistochemical analysis of cytochrome P450 1B1 expression in human normal tissues. J Histochem Cytochem 2001;49:229-36.
4. Liu J, Wang Q, Wu D, et al. Differential regulation of CYP1A1 and CYP1B1 expression in resveratrol-treated human medulloblastoma cells. Neurosci Lett 2004;363:257-61.
5. Gribben JG, Ryan DP, Boyajian R, et al. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to the next therapy. Clin Cancer Res 2005;11:4430-6.
6. Patterson LH. Bioreductively activated antitumor N-oxides: the case of AQ4N, a unique approach to hypoxia-activated cancer chemotherapy. Drug Metab Rev 2002;34:581-92.
7. Patterson LH, McKeown SR. AQ4N: a new approach to hypoxia-activated cancer chemotherapy. Br J Cancer 2000;83:1589-93.
8. Yu J, Liu G, Ying H, Yong W, Black K, Wheeler CJ. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 2004;64:4973-9.
9. Liau LM, Prins RM, Kiertscher SM, et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 2005;11:5515-25.
10. Archer GE, Bigner DD, Friedman AH, Heimberger AB, Sampson J. Induction of CD4 and CD8 T-cells to the tumor specific antigen EGFRvIII. Fifteenth International Conference on Brain Tumor Research and Therapy, May 24-27, 2003, Sorrento, Italy. Neuro-Oncol 2003;5:375.
11. Heimberger AB, Hussain SF, Suki D, et al. An epidermal growth factor receptor variant III peptide vaccination appears promising in newly diagnosed GBM patients: preliminary results of a randomized phase II clinical trial. San Francisco (CA): 74th Annual Meeting of the American Association of Neurological Surgeons; 2006.
12. Heimberger AB, Crotty LE, Archer GE, et al. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res 2003;9:4247-54.
13. Heimberger AB, McGary E, Suki D, et al. Loss of the AP-2α transcription factor is associated with the grade of human gliomas. Clin Cancer Res 2005;11:267-72.
14. Heimberger AB, Hlatky R, Suki D, et al. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res 2005;11:1462-6.
15. Kumarakulasingham M, Rooney PH, Dundas SR, et al. Cytochrome p450 profile of colorectal cancer: identification of markers of prognosis. Clin Cancer Res 2005;11:3758-65.
16. McFadyen MC, Breeman S, Payne S, et al. Immunohistochemical localization of cytochrome P450 CYP1B1 in breast cancer with monoclonal antibodies specific for CYP1B1. J Histochem Cytochem 1999;47:1457-64.
17. Doshi M, Marcus C, Bejjani BA, Edward DP. Immunolocalization of CYP1B1 in normal, human, fetal and adult eyes. Exp Eye Res 2006;82:24-32.
18. Downie D, McFadyen MC, Rooney PH, et al. Profiling cytochrome p450 expression in ovarian cancer: identification of prognostic markers. Clin Cancer Res 2005;11:7369-75.
19. Shinojima N, Tada K, Shiraishi S, et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 2003;63:6962-70.
20. Leins A, Riva P, Lindstedt R, Davidoff MS, Mehraein P, Weis S. Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma. Cancer 2003;98:2430-9.
21. Chakravarti A, Noll E, Black PM, et al. Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J Clin Oncol 2002;20:1063-8.
22. Aklillu E, Ovrebo S, Botnen IV, Otter C, Ingelman-Sundberg M. Characterization of common CYP1B1 variants with different capacity for benzo[a]pyrene-7, 8-dihydrodiol epoxide formation from benzo[a]pyrene. Cancer Res 2005;65:5105-11.
23. Watanabe K, Sato K, Biernat W, et al. Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin Cancer Res 1997;3:523-30.
24. Mclendon RE, Herndon JE, West B, et al. Survival analysis of presumptive prognostic markers among oligodendrogliomas. Cancer 2005;104:1693-9.
25. Hagel C, Laking G, Laas R, et al. Demonstration of p53 protein and TP53 gene mutations in oligodendrogliomas. Eur J Cancer 1996;32A:2242-8.
26. Watanabe T, Nakamura M, Kros JM, et al. Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas. Acta Neuropathol 2002;103:267-75.
27. DeRoos AJ, Rothman N, Brown M, et al. Variation in genes relevant to aromatic hydrocarbon metabolism and the risk of adult brain tumors. Neuro-oncol 2006;8:145-55.
28. Rodriguez-Melendez R, Griffin JB, Zempleni J. Biotin supplementation increases expression of the cytochrome P450 1B1 gene in Jurkat cells, increasing the occurrence of single-stranded DNA breaks. J Nutr 2004;134:2222-8.
29. Patterson LH, Murray GI. Tumour cytochrome P450 and drug activation. Curr Pharm Des 2002;8:1335-47.
30. Kivisto KT, Kroemer HK, Eichelbaum M. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br J Clin Pharmacol 1995;40:523-30.
31. Achary MP, Jaggernauth W, Gross E, Alfieri A, Klinger HP, Vikram B. Cell lines from the same cervical carcinoma but with different radiosensitivities exhibit different cDNA microarray patterns of gene expression. Cytogenet Cell Genet 2000;91:39-43.